ASH 2025 | Latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Alexey Danilov, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What are the latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)? 

This educational resource is independently supported by Nurix. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.